Why the study?
Doxorubicin use is limited by cardiotoxicity, and while cardiac IF1 expression increases in pathological conditions, its role in chemotherapy-induced cardiotoxicity remains unclear.
Does IF1 deficiency attenuate doxorubicin-induced cardiotoxicity in preclinical models?
Population
Male C57BL/6J WT and IF1KO mice, isolated cardiac mitochondria, cultured neonatal cardiomyocytes, and AC16 human cardiomyocytes
Comparison
IF1 deficiency or dominant-negative mutant vs wild-type under doxorubicin stress
Design
Preclinical laboratory and animal study
Key result
IF1 deficiency attenuated cardiac dysfunction and improved myocardial ultrastructure following doxorubicin treatment compared with wild-type mice.
Authors
Loading...
Supports IF1 as a target in doxorubicin cardiotoxicity; leaves open clinical translation.
Does IF1 deficiency attenuate doxorubicin-induced cardiotoxicity in preclinical models?
IF1 deficiency attenuates doxorubicin-induced cardiotoxicity by preserving mitochondrial structure and function, identifying IF1 as a potential therapeutic target in cardio-oncology.
Mobasheran et al. (2026) studied Doxorubicin-induced cardiotoxicity. IF1 deficiency (IF1 knockout) vs. Wild-type (WT) was evaluated on Cardiac dysfunction and myocardial ultrastructure. IF1 deficiency attenuated cardiac dysfunction and improved myocardial ultrastructure following doxorubicin treatment compared with wild-type mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: